SCHEMBL16615921

SCHEMBL16615921

Cc1ncc(CNC(=O)c2cnc(CNS(=O)(=O)c3cc(Cl)ccc3F)c(C)n2)s1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2A Q12879 4/20 0.75
GRIN1 Q05586 2/20 0.75
GRIN2B Q13224 1/20 0.75
SMN1; SMN2 Q16637 2/20 0.38
SCD O00767 1/20 0.38
MAPT P10636 4/20 0.36
MEN1 O00255 1/20 0.36
MAPK1 P28482 1/20 0.36
HTT P42858 1/20 0.36
KMT2A Q03164 1/20 0.36
GRM4 Q14833 1/20 0.35
DDR1 Q08345 3/20 0.35
ALPL P05186 1/20 0.34
CXCR4 P61073 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
LMNA P02545 3/20 0.33
TP53 P04637 3/20 0.33
SGK1 O00141 1/20 0.33
NR3C1 P04150 1/20 0.33
NR3C2 P08235 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16615924 0.89 GRIN2A (0.73) GRIN2AGRIN1GRIN2BSMN1; SMN2SCD
SCHEMBL16598208 0.87 GRIN2A (0.85) GRIN2AGRIN1GRIN2BSCDMAPT
SCHEMBL30151536 0.86 GRIN2A (1.00) GRIN2AGRIN1GRIN2BSCDMAPT
SCHEMBL16615945 0.86 GRIN2A (0.77) GRIN2AGRIN1GRIN2BSMN1; SMN2SCD
SCHEMBL16615815 0.86 GRIN2A (1.00) GRIN2AGRIN1GRIN2BSCDMAPT
SCHEMBL16615959 0.85 GRIN2A (0.85) GRIN2AGRIN1GRIN2BSCDMAPK1
SCHEMBL16615958 0.85 GRIN2A (0.77) GRIN2AGRIN1GRIN2BSMN1; SMN2MEN1
SCHEMBL16598124 0.85 GRIN2A (0.60) GRIN2AGRIN1GRIN2BSMN1; SMN2SCD
SCHEMBL16615821 0.85 GRIN2A (0.65) GRIN2AGRIN1GRIN2BSCDMAPT
SCHEMBL16615955 0.85 GRIN2A (0.76) GRIN2AGRIN1GRIN2BSMN1; SMN2SCD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9963434-B2 N-arylmethyl sulfonamide negative modulators of NR2A LUC THERAPEUTICS, INC. (US) 2018-05-08 US disclosed
US-9963434-B2 N-arylmethyl sulfonamide negative modulators of NR2A LUC THERAPEUTICS, INC. (US) 2018-05-08 US disclosed
US-20160311782-A1 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A NOVARTIS AG (CH) 2016-10-27 US disclosed
US-20160311782-A1 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A NOVARTIS AG (CH) 2016-10-27 US disclosed
US-20150141433-A1 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A MNEMOSYNE PHARMACEUTICALS, INC. 2015-05-21 US disclosed
US-20150141433-A1 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A MNEMOSYNE PHARMACEUTICALS, INC. 2015-05-21 US disclosed
WO-2015048503-A2 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A MNEMOSYNE PHARMACEUTICALS, INC. (US) 2015-04-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160311782-A1 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A GRIN2A, GRIN2B, NR2C2 GRIN2A 1/4885GRIN1 5/4885GRIN2B 2/4885
US-20150141433-A1 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A GRIN2A, GRIN2B, NR2C2 GRIN2A 1/4885GRIN1 5/4885GRIN2B 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.